全文获取类型
收费全文 | 11669篇 |
免费 | 933篇 |
国内免费 | 43篇 |
专业分类
耳鼻咽喉 | 158篇 |
儿科学 | 245篇 |
妇产科学 | 167篇 |
基础医学 | 1376篇 |
口腔科学 | 156篇 |
临床医学 | 1214篇 |
内科学 | 2424篇 |
皮肤病学 | 174篇 |
神经病学 | 938篇 |
特种医学 | 411篇 |
外科学 | 2396篇 |
综合类 | 152篇 |
一般理论 | 13篇 |
预防医学 | 932篇 |
眼科学 | 323篇 |
药学 | 686篇 |
中国医学 | 13篇 |
肿瘤学 | 867篇 |
出版年
2024年 | 17篇 |
2023年 | 155篇 |
2022年 | 231篇 |
2021年 | 608篇 |
2020年 | 315篇 |
2019年 | 511篇 |
2018年 | 578篇 |
2017年 | 392篇 |
2016年 | 388篇 |
2015年 | 416篇 |
2014年 | 585篇 |
2013年 | 686篇 |
2012年 | 1059篇 |
2011年 | 998篇 |
2010年 | 552篇 |
2009年 | 438篇 |
2008年 | 674篇 |
2007年 | 652篇 |
2006年 | 593篇 |
2005年 | 534篇 |
2004年 | 457篇 |
2003年 | 404篇 |
2002年 | 299篇 |
2001年 | 78篇 |
2000年 | 62篇 |
1999年 | 87篇 |
1998年 | 48篇 |
1997年 | 41篇 |
1996年 | 44篇 |
1995年 | 28篇 |
1994年 | 23篇 |
1993年 | 24篇 |
1992年 | 51篇 |
1991年 | 44篇 |
1990年 | 41篇 |
1989年 | 36篇 |
1988年 | 32篇 |
1987年 | 28篇 |
1986年 | 25篇 |
1985年 | 19篇 |
1984年 | 29篇 |
1983年 | 24篇 |
1982年 | 21篇 |
1980年 | 19篇 |
1979年 | 31篇 |
1978年 | 29篇 |
1976年 | 20篇 |
1974年 | 24篇 |
1969年 | 18篇 |
1968年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Marisa L Kreider Justin E Aldridge Mandy M Cousins Colleen A Oliver Frederic J Seidler Theodore A Slotkin 《Neuropsychopharmacology》2005,30(10):1841-1855
Glucocorticoids are the consensus treatment for the prevention of respiratory distress in preterm infants, but there is evidence for increased incidence of neurodevelopmental disorders as a result of their administration. We administered dexamethasone (Dex) to developing rats at doses below or within the range of those used clinically, evaluating the effects on forebrain development with exposure in three different stages: gestational days 17-19, postnatal days 1-3, or postnatal days 7-9. At 24 h after the last dose, we evaluated biomarkers of neural cell acquisition and growth, synaptic development, neurotransmitter receptor expression, and synaptic signaling mediated by adenylyl cyclase (AC). Dex impaired the acquisition of neural cells, with a peak effect when given in the immediate postnatal period. In association with this defect, Dex also elicited biphasic effects on cholinergic presynaptic development, promoting synaptic maturation at a dose (0.05 mg/kg) well below those used therapeutically, whereas the effect was diminished or lost when doses were increased to 0.2 or 0.8 mg/kg. Dex given postnatally also disrupted the expression of adrenergic receptors known to participate in neurotrophic modeling of the developing brain and evoked massive induction of AC activity. As a consequence, disparate receptor inputs all produced cyclic AMP overproduction, a likely contributor to disrupted patterns of cell replication, differentiation, and apoptosis. Superimposed on the heterologous AC induction, Dex impaired specific receptor-mediated cholinergic and adrenergic signals. These results indicate that, during a critical developmental period, Dex administration leads to widespread interference with forebrain development, likely contributing to eventual, adverse neurobehavioral outcomes. 相似文献
92.
Janet Li Paul Roche Jenean Spencer Ivan Bastian Amanda Christensen Mark Hurwitz Anastasios Konstantinos Vicki Krause Moira McKinnon Avner Misrachi Graham Tallis Justin Waring 《Communicable diseases intelligence》2004,28(4):464-473
The National Notifiable Disease Surveillance System (NNDSS) received 982 tuberculosis (TB) notifications in 2003, of which 947 were new cases, 33 were relapses and two were cases with unknown history. The incidence of TB in Australia has remained at a stable rate since 1985 and was 4.9 cases per 100,000 population in 2003. The high-incidence groups remain people born overseas and Indigenous Australians at 19.9 and 8.7 cases per 100,000 population, respectively. By contrast the incidence in non-Indigenous Australians was 0.9 per 100,000. Comparison of the 2003 TB notification data against the performance indicators set by National Tuberculosis Advisory Committee highlights that enhanced TB control measures should be considered among these high-risk groups. 相似文献
93.
Louis B Cooper Dylan K Chan Frederick C Roediger Brian R Shaffer Justin F Fraser Sergei Musatov Samuel H Selesnick Michael G Kaplitt 《Otology & neurotology》2006,27(4):484-490
HYPOTHESIS: Delivery of the gene encoding X-linked inhibitor of apoptosis (XIAP) using an adeno-associated viral (AAV) vector can protect against cisplatin-mediated ototoxicity. BACKGROUND: Cisplatin is a widely used chemotherapeutic agent with significant ototoxic side effects. One possible mechanism of toxicity is apoptotic death of many cochlear cell types. Acute treatment with inhibitors of caspases- enzymes critical for apoptosis- has been shown to prevent hearing loss in vivo, but is too short-acting for therapeutic use. Gene therapy provides a specific and chronic means of delivering potential therapeutic gents. Introducing an anti-apoptotic gene into the cochlea could provide long-term prophylaxis against the ototoxic effects of cisplatin. METHOD: Two groups of rats were treated with unilateral injection into the round window of AAV harboring a gene encoding either XIAP or green fluorescent protein (GFP). After at least two months of gene expression, auditory-brainstem-response (ABR) threshold shifts and outer-hair-cell (OHC) number were measured in these two groups of animals after 72-hour treatment with cisplatin. RESULTS: Consistent with previous reports, uninjected and AAV.GFP-injected ears displayed profound ABR threshold elevations and OHC loss after cisplatin treatment. Ears that had been injected with AAV encoding XIAP, however, were significantly protected from these effects: cisplatin-induced ABR-threshold shift and hair-cell loss were attenuated by as much as 78% and 45%, respectively, when compared with contralateral (untreated) ears. CONCLUSION: XIAP delivery to the cochlea can protect against the audiometric changes and hair-cell loss associated with cisplatin ototoxicity. The efficacy, specificity, and duration of the protective effects make this a potentially attractive therapeutic paradigm. 相似文献
94.
Dan W Haupt Angela Luber Justin Maeda Angela K Melson Julie A Schweiger John W Newcomer 《Neuropsychopharmacology》2005,30(1):184-191
Alterations in plasma leptin have been reported in schizophrenia patients treated with antipsychotics, suggesting the hypothesis that impairments in leptin secretion or signaling might play a role in antipsychotic-induced weight gain. Plasma leptin was measured in 72 schizophrenia patients chronically treated with olanzapine (n=27), risperidone (n=24) or typical antipsychotics (n=21) and 124 healthy adult control subjects. ANCOVA was used to test effects of adiposity (body mass index kg/m2; BMI), subject group (treated patients vs untreated controls), and treatment group (specific medication groups and untreated controls) on plasma leptin concentrations. Additional analyses were performed in a subset of patients and controls individually matched for BMI to further assess group differences in plasma leptin independent of adiposity. BMI strongly predicted plasma leptin concentrations in the overall sample. In addition, a significant three-way interaction between BMI, subject group, and gender was observed. In the individually BMI-matched sample, modestly reduced plasma leptin levels (effect size 0.4 SD) were observed in treated patients in comparison to the BMI-matched healthy controls, with both groups including males and females. However, no differences in plasma leptin levels were observed in the matched sample when separately comparing male patients vs untreated male controls and female patients vs untreated female controls. Plasma leptin in chronically treated patients with schizophrenia is strongly predicted by adiposity, similar to untreated healthy individuals despite adequate power to detect a difference. The results argue against a role for defective leptin secretion or sensitivity in the weight gain induced by antipsychotic medications. 相似文献
95.
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. 总被引:7,自引:0,他引:7
E Ramsay Camp Justin Summy Todd W Bauer Wenbiao Liu Gary E Gallick Lee M Ellis 《Clinical cancer research》2005,11(1):397-405
Targeted therapies that inhibit the activity of tyrosine kinase receptors such as the epidermal growth factor receptor (EGFR) have shown activity against solid malignancies when used as single agents or in combination with chemotherapy. Although anti-EGFR therapies are active in some patients, eventually disease in nearly all patients will become refractory to therapy. Therefore, a better understanding of the mechanisms of resistance to anti-EGFR therapies is critical to further improve the efficacy of this class of agents. Mechanisms that mediate resistance to anti-EGFR therapies include the presence of redundant tyrosine kinase receptors, increased angiogenesis, and the constitutive activation of downstream mediators. Two recent landmark publications have also shown that specific mutations in the kinase domain of EGFR in some lung carcinomas are associated with markedly improved response rates to an EGFR tyrosine kinase inhibitor. Mutations in the EGFR receptor seem to play a significant role in determining the sensitivity of tumor cells to EGFR inhibitor therapy by altering the conformation and activity of the receptor. As the field of molecular therapeutics continues to evolve, a comprehensive understanding of resistance mechanisms will ultimately lead to refinements in our regimens to provide better care for patients with cancer. 相似文献
96.
97.
Steven P Treon Mark Hansen Andrew R Branagan Sigitas Verselis Christos Emmanouilides Eva Kimby Stanley R Frankel Nikolaos Touroutoglou Barry Turnbull Kenneth C Anderson David G Maloney Edward A Fox 《Journal of clinical oncology》2005,23(3):474-481
PURPOSE: Rituximab is an important therapeutic for Waldenstrom's macroglobulinemia (WM). Polymorphisms in FcgammaRIIIA (CD16) receptor expression modulate human immunoglobulin G1 binding and antibody-dependent cell-mediated cytotoxicity, and may therefore influence responses to rituximab. PATIENTS AND METHODS: Sequence analysis of the entire coding region of FcgammaRIIIA was undertaken in 58 patients with WM whose outcomes after rituximab were known. RESULTS: Variations in five codons of FcgammaRIIIA were identified. Two were commonly observed (FcgammaRIIIA-48 and FcgammaRIIIA-158) and predicted for amino acid polymorphisms at FcgammaRIIIA-48: leucine/leucine (L/L), leucine/arginine (L/R), and leucine/histidine (L/H). Polymorphisms at FcgammaRIIIA-158 were phenylalanine/phenylalanine (F/F), phenylalanine/valine (F/V), and valine/valine (V/V). A clear linkage between these polymorphisms was detected and all patients with FcgammaRIIIA-158F/F were always FcgammaRIIIA-48L/L, and patients with either FcgammaRIIIA-L/R or -L/H always expressed at least one valine at FcgammaRIIIA-158 (P < or = .001). The response trend was higher for patients with FcgammaRIIIA-48L/H (38.5%) versus -48L/R (25.0%) and LL (22.0%), and was significantly higher for patients with FcgammaRIIIA-158V/V (40.0%) and -V/F (35%) versus -158F/F (9.0%; P = .030). Responses for patients with FcgammaRIIIA-48L/L were higher when at least one valine was present at FcgammaRIIIA-158 (P = .057), thereby supporting a primary role for FcgammaRIIIA-158 polymorphisms in predicting rituximab responses. With a median follow-up of 13 months, no significant differences in the median time to progression and progression-free survival were observed when patients were grouped according to their FcgammaRIIIA-48 and -158 polymorphisms. CONCLUSION: The results of these studies therefore support a predictive role for FcgammaRIIIA-158 polymorphisms and responses to rituximab in WM. 相似文献
98.
99.
Sadikah Behbehani Stefano Polesello Joseph Hasson Justin Silver Weon-Young Son Michael Dahan 《Journal of minimally invasive gynecology》2018,25(7):1241-1248
Study Objective
To assess clinical pregnancy rate (CPR) and live birth rate (LBR) in the presence of non–cavity-deforming intramural myomas in single fresh blastocyst transfer cycles.Design
Retrospective cohort study (Canadian Task Force classification II-2).Setting
Academic fertility center.Patients
A total of 929 fresh single blastocyst transfer cycles were included, 94 with only non–cavity-distorting intramural myomas and 764 without myomas. Cleavage embryo transfers were excluded to reduce bias based on embryo quality.Interventions
None.Measurements and Main Results
CPR and LBR were assessed. There were no differences noted in gravidity, parity, or body mass index between patients with myomas and those without myomas. Women with myomas required higher doses of gonadotropins (mean, 2653?±?404?IU vs 2350?±?1368?IU; p?=?.04) than women without myomas. However, the total number of mature oocytes collected and the total number of blastocysts created were similar. CPR (47% vs 32%; p?=?.005) and LBR (37.8% vs 25.5%; p?=?.02) were lower in patients who had intramural myomas compared with those without myomas. CPR and LBR were significantly reduced in the presence of even 1 myoma (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.33–0.83 and OR, 0.56; 95% CI, 0.35–0.92, respectively). In patients with myomas >1.5?cm, LBR was also significantly reduced, even after adjusting for age, smoking, quality of embryo transferred, antral follicle count, and dose of gonadotropins (OR, 0.53; 95% CI, 0.29–0.97). This LBR finding was not significant if all myomas were included (including those <1.5?cm in diameter), but CPR was still significantly reduced.Conclusion
Relatively small (>1.5?cm) non–cavity-distorting intramural myomas negatively affect CPR and LBR in in vitro fertilization cycles, even in the presence of only 1 myoma. 相似文献100.
David N. Hackney Kelly Kuo Rebecca J. Petersen Justin R. Lappen 《The journal of maternal-fetal & neonatal medicine》2016,29(2):258-263
Objective: Patients with PPROM are at risk for a variety of outcomes, including chorioamnionitis (CA), placental abruption (PA), or preterm labor (PTL). Competing risk regression can analyze a cohort’s risk of individual outcomes while accounting for ongoing deliveries secondary to competing events.Methods: A secondary analysis of the subjects from MFMU BEAM study of neuroprotection after preterm birth (BEAM) with conservative PPROM management. Deliveries were categorized as: PA, CA, PTL, “elective” or “indicated”. The association between outcomes of PA, CA or PTL and clinical predictors of twins, ethnicity, parity, gestational age at rupture, bleeding, contractions, cervical dilation, preterm birth history, weight, and genitourinary infections were evaluated via competing risk regression.Result: 1970 subjects were included. The significance and directionality of predictors varied according to specific outcomes. Patients with twins had an increased PTL hazard (1.85) though reductions in CA- (0.66) or PA-specific (0.56) hazards. Decreased latency in African-Americans was almost entirely due to an increased CA hazard (1.44) without a significant association with PTL. Increasing gestational age at membrane rupture was associated with a decreasing hazard of CA although increasing hazard of PTL.Conclusions: For patients with PPROM, the hazards associated with different clinical predictors vary according to exact outcomes. 相似文献